Disc Medicine
NASDAQ:IRONDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Global X S&P 500 Tail Risk ETF
NYSEARCA:XTRThe Global X S&P 500 Tail Risk ETF (XTR) is an exchange-traded fund that is based on the Cboe S&P 500 Tail Risk index. The fund tracks an index of the S&P 500 stocks and aims to protect the fund from significant negative movements or tail risk by purchasing quarterly Index put options. XTR was launched on Aug 25, 2021 and is managed by Global X.